BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9682030)

  • 1. Screen compliance rates in 14-years annual screening program for colorectal cancer with immunochemical fecal occult blood test-- identification of higher priority subjects in health education.
    Wei N; Nakama H; Li T
    Eur J Med Res; 1998 Jul; 3(7):341-4. PubMed ID: 9682030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of colorectal cancer stage among HMO members targeted for screening.
    Myers RE; Murray J; Weinberg D; McGrory G; Wolf T; Caveny J; Hanchak N; Schlackman N; Comis R
    Arch Intern Med; 1997 Sep; 157(17):2001-6. PubMed ID: 9308512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reasons for non-compliance in colorectal cancer screening with fecal occult blood test.
    Li T; Nakama H; Wei N
    Eur J Med Res; 1998 Aug; 3(8):397-400. PubMed ID: 9707523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Feasibility of colorectal cancer screening with fecal occult blood test distributed by public pharmacies].
    Pippa G; Ferrara M; Valle S; Diego B; Alessandra B; Apuzzo M; Bazuro ME; Tammaro G; Federici A
    Recenti Prog Med; 2009; 100(7-8):348-51. PubMed ID: 19725474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy.
    Heitman SJ; Au F; Manns BJ; McGregor SE; Hilsden RJ
    Clin Gastroenterol Hepatol; 2008 Aug; 6(8):912-917.e1. PubMed ID: 18534918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
    Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer.
    Parente F; Marino B; DeVecchi N; Moretti R; ; Ucci G; Tricomi P; Armellino A; Redaelli L; Bargiggia S; Cristofori E; Masala E; Tortorella F; Gattinoni A; Odinolfi F; Pirola ME
    Br J Surg; 2009 May; 96(5):533-40. PubMed ID: 19358181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Physicians' reminders promote annual fecal occult blood testing compliance].
    Vinker S; Shumla V; Kitai E
    Harefuah; 2000 Jun; 138(12):1019-21, 1088, 1087. PubMed ID: 10979422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of immunological fecal occult blood testing for colorectal cancer screening.
    Nakama H; Kamijo N
    Prev Med; 1994 May; 23(3):309-13. PubMed ID: 8078851
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survey of the opinions, knowledge, and practices of gastroenterologists regarding colorectal cancer screening and use of the fecal occult blood test.
    Sharma VK; Corder FA; Fancher J; Howden CW
    Am J Gastroenterol; 2000 Dec; 95(12):3629-32. PubMed ID: 11151904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limitations of the faecal occult blood test in screening for colorectal cancer.
    Delcò F; Sonnenberg A
    Ital J Gastroenterol Hepatol; 1999 Mar; 31(2):119-26. PubMed ID: 10363196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics and survival rate of elderly patients with colorectal cancer detected by immunochemical occult blood screening.
    Zhang B; Fattah A; Nakama H
    Hepatogastroenterology; 2000; 47(32):414-8. PubMed ID: 10791202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychological and behavioral factors associated with colorectal cancer screening among Ashkenazim.
    Friedman LC; Webb JA; Richards CS; Plon SE
    Prev Med; 1999 Aug; 29(2):119-25. PubMed ID: 10446038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized controlled trial of the impact of intensive patient education on compliance with fecal occult blood testing.
    Stokamer CL; Tenner CT; Chaudhuri J; Vazquez E; Bini EJ
    J Gen Intern Med; 2005 Mar; 20(3):278-82. PubMed ID: 15836533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measuring the quality of colorectal cancer screening: the importance of follow-up.
    Etzioni DA; Yano EM; Rubenstein LV; Lee ML; Ko CY; Brook RH; Parkerton PH; Asch SM
    Dis Colon Rectum; 2006 Jul; 49(7):1002-10. PubMed ID: 16673056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Digital rectal fecal occult blood screening during gynecologic examination.
    Willis FL; Fanning J
    Am J Obstet Gynecol; 2004 May; 190(5):1422-3. PubMed ID: 15167856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing.
    Helm JF; Russo MW; Biddle AK; Simpson KN; Ransohoff DF; Sandler RS
    Am J Gastroenterol; 2000 Nov; 95(11):3250-8. PubMed ID: 11095350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving colorectal cancer screening in a medical residents' primary care clinic.
    Struewing JP; Pape DM; Snow DA
    Am J Prev Med; 1991; 7(2):75-81. PubMed ID: 1910891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implementation of colorectal cancer screening in Finland: experiences from the first three years of a public health programme.
    Malila N; Oivanen T; Hakama M
    Z Gastroenterol; 2008 Apr; 46 Suppl 1():S25-8. PubMed ID: 18368636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Colonoscopy results of a French regional FOBT-based colorectal cancer screening program with high compliance.
    Manfredi S; Piette C; Durand G; Plihon G; Mallard G; Bretagne JF
    Endoscopy; 2008 May; 40(5):422-7. PubMed ID: 18231963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.